Is The Increase In Orchiectomy For Prostate Cancer Patients Appropriate?
Main Category: Prostate / Prostate CancerAlso Included In: Urology / Nephrology
Article Date: 30 May 2008 - 0:00 PDT
| Patient / Public: | ![]() |
4.33 (3 votes) |
| Healthcare Prof: | ![]() |
3 (1 votes) |
UroToday.com - In the online version of Cancer, Gerald W. Chodak writes an editorial on the article "Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population.", (Cancer. 2008;epub) from Dr. Weight and colleagues at the Cleveland Clinic.
He points out how the Medicare Modernization Act reduced reimbursement for the overly high compensation of LHRH agonist administration. Prior to this, less that 9% of men in the US receiving androgen deprivation therapy (ADT) got orchiectomies. Now orchiectomies are increasing and LHRH agonist use decreasing.
He also points out that most patients treated with ADT do not need it long term, and for them surgical castration would be inappropriate. However, there is no data as to who is now undergoing surgical castration to answer this question. Dr. Chodak feels that the data regarding intermittent ADT is not yet the standard, otherwise surgical castration would be inappropriate for these patients as well.
Since the increase in orchiectomy has not completely offset the drop in LHRH use, he suggests that economics are not the sole reason for the change in practice. The reimbursement rate of an LHRH agonist was 106% of allowable wholesale cost and this could mean a financial loss to the provider if any but one drug spared from this calculation is used. Urologists often give the prescription and ask the patient to take the drug to the clinic for injection to avoid this loss.
He concludes that an open discussion with the patients is best to determine the most appropriate form of ADT in an individual.
Reported by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to: www.urotoday.com
Copyright © 2008 - UroToday
Visit our prostate / prostate cancer section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/109219.php>
APA
http://www.medicalnewstoday.com/releases/109219.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




